Clinical trial · Interventional
Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260917-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to assess the feasibility of an 8-week aerobic exercise program and its effect on arterial function in breast cancer survivors. The main questions it aims to answer are: * Is an 8-week aerobic exercise program feasible in breast cancer survivors after the completion of chemotherapy, immunotherapy and/or anti-HER2 agents? * Is this 8-week aerobic exercise program beneficial for vascular function in breast cancer survivors? Participants will: * Begin an 8-week aerobic exercise program, three days per week, after the completion of chemotherapy, immunotherapy and/or anti-HER2 agents. * Visit our facility three times: before the exercise program, 1 month after, and after the completion of the program. * Complete questionnaires, physical functional tests, and body composition and vascular measurements at every visit.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Survivors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aerobic Exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Exercise Intervention
- interventionNames
- Other: Aerobic Exercise
Primary outcomes (5)
- measure
- Enrollment (Recruitment rate)
- timeFrame
- From enrollment to immediately after first visit
- description
- Enrollment will be measured by the proportion of eligible breast cancer survivors who provide informed consent to participate in the study. The proportion of enrolled participants will be reported.
- measure
- Participant adherence - Proportion of people considered adherent
- timeFrame
- From enrollment to the end of intervention at 8 weeks
- description
- Adherence will be measured as the proportion of exercise sessions completed by consented survivors out of the total of 24 prescribed training sessions. Completion of at least 18 of the 24 training sessions will be considered adherent.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion criteria: 1. Women (18-70 years) with a stage I-III breast cancer diagnosis who have completed chemotherapy, immunotherapy and/or anti-HER2 agents. 2. Able to begin aerobic exercise within 12 weeks of the final chemotherapy, immunotherapy and/or anti-HER2 agents. 3. Sedentary by self-reporting inactivity (\<90 min of moderate or vigorous exercise per week) 4. Weight ≤154 kg 5. Willing to complete all study activities 6. Able to safely participate in moderate aerobic exercise. Exclusion criteria: 1. Current pregnant and lactating patients. Must have completed lactation prior to study start. 2. Metastatic disease. 3. Diagnosed cardiovascular disease prior to the initiation of cancer therapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%. 4. Non-English speaking
References
Publications (0)
Data not yet available